Wiersma J J, Trip M D, Piek J J
Universiteit van Amsterdam, afd. Cardiologie, B2-224, Meibergdreef 9, 1105 AZ Amsterdam.
Ned Tijdschr Geneeskd. 2006 Feb 18;150(7):361-6.
Of all patients presenting with coronary, artery disease, 20-30% already have a diagnosis of diabetes mellitus type 2. Of the remaining patients, another 15-20% are found at presentation to have diabetes mellitus and 30% have glucose intolerance. Both conditions are major risk factors for the recurrence of coronary artery disease and mortality. The treatment of patients with diabetes mellitus type 2 always includes improvement in lifestyle, adequate blood-glucose control, cholesterol-lowering therapy and blood-pressure control. Furthermore, if one or more other traditional cardiovascular risk factors are present, or if the patient is over 40 years of age, acetylsalicylic acid must be added. Finally, with a prior history of coronary-artery disease, patients must be given an angiotensin converting enzyme (ACE) inhibitor. During percutaneous coronary interventions, patients with diabetes mellitus type 2 are preferably treated with a drug-eluting stent in combination with clopidogrel, and in case of an acute coronary syndrome, glycoprotein (GP) IIb/IIIa receptor antagonists are added to the standard treatment.
在所有患有冠状动脉疾病的患者中,20% - 30%已被诊断为2型糖尿病。在其余患者中,另有15% - 20%在就诊时被发现患有糖尿病,30%有糖耐量异常。这两种情况都是冠状动脉疾病复发和死亡的主要危险因素。2型糖尿病患者的治疗始终包括改善生活方式、充分控制血糖、降低胆固醇治疗和控制血压。此外,如果存在一种或多种其他传统心血管危险因素,或者患者年龄超过40岁,必须加用乙酰水杨酸。最后,有冠状动脉疾病既往史的患者必须给予血管紧张素转换酶(ACE)抑制剂。在经皮冠状动脉介入治疗期间,2型糖尿病患者最好使用药物洗脱支架联合氯吡格雷进行治疗,如发生急性冠状动脉综合征,则在标准治疗中加用糖蛋白(GP)IIb/IIIa受体拮抗剂。